Acumen Pharmaceuticals reported its financial results for the second quarter of 2025, with cash, cash equivalents, and marketable securities expected to fund operations into early 2027. The company's momentum reflects strong operational execution and the broadening portfolio with the addition of the Enhanced Brain Delivery (EBD™) program.
The company anticipates producing a non-clinical data package for its EBD program in early 2026, which will inform its development strategy. This new program, a collaboration with JCR Pharmaceuticals, aims to develop oligomer-targeted antibodies with blood-brain barrier-penetrating technology.
Acumen reiterated its expectation for topline results from the Phase 2 ALTITUDE-AD study in late 2026. The company believes its current portfolio positions it to deliver next-generation treatment options for early Alzheimer’s disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.